Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach

Shinder, Brian; Rhee, Kevin; Farrell, Douglas; Farber, Nicholas; Stein, Mark N.; Jang, Thomas L.; Singer, Eric A.

doi:10.3389/fonc.2017.00107

Cited by 53 publications

(38 citation statements)

References 163 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The major type of kidney tumor (80-90%) originates from the epithelial lining of the proximal convoluted tubules and exhibits highly vascularized and metastatic characteristics (2). To date, the primary therapy for localized RCC is surgery (radical nephrectomy and nephron-sparing surgery), while for unresectable and metastatic RCC, the therapeutic options remain limited (3)(4)(5). RCC is sensitive to neither traditional chemotherapy nor radiation therapy (6).…”

Section: Introductionmentioning

confidence: 99%

Andrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death receptor 4

Deng

Tang

et al. 2020

Oncol Rep

View full text Add to dashboard Cite

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells, with minimal toxicity to normal tissues. However, accumulating evidence suggests that certain cancer types are insensitive to TRAIL signaling. The aim of this study was to identify an effective combination regimen, which can overcome TRAIL resistance in renal cancer cell. Herein, we found that human renal carcinoma cells (RCCs) are widely resistant to TRAIL-mediated growth inhibition and subsequently identified that andrographolide (Andro), a major constituent of Andrographis paniculate, an annual herbaceous plant in the family Acanthaceae, counteracts TRAIL resistance in RCCs. Combined treatment with TRAIL and Andro suppressed cell viability as determined by MTS and proliferation as determined by EdU in a dose-dependent manner and inactivated the clonogenic and migration ability of RCCs. Andro significantly enhances TRAIL-mediated cell cycle arrest at the G2/M phase as determined by flow cytometry and senescence. Moreover, Andro restored TRAIL signaling, which in turns activated pro-apoptosis caspases as determined by immunoblot assay. The TRAIL receptor, death receptor (DR)4, but not DR5, was found to be significantly upregulated in Andro-treated RCC cells, which contributed to the role of Andro as a TRAIL sensitizer. The present study demonstrated that the combined treatment of Andro and TRAIL has potential therapeutic value against renal cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Andrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death receptor 4

Deng

Tang

et al. 2020

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Renal cell cancer (RCC) runs up to 3% of malignant tumors in human beings each year, and surgical resection of these tumors generally results in excellent long-term disease-free survival [1] . However, studies revealed that 20–50% of patients present with locally advanced and distant metastatic disease [2] . Moreover, patients with metastatic RCC (mRCC) of other organs represent an unfavorable subset of individuals.…”

Section: Introductionmentioning

confidence: 99%

Risk factors for bone metastasis from renal cell cancer

Chen

Lan

Zhou

et al. 2017

Journal of Bone Oncology

View full text Add to dashboard Cite

ObjectiveThe prognosis for renal cell carcinoma (RCC) is related to a high rate of metastasis, including 30% of bone metastasis. In this study, we investigate the correlation between diverse clinical factors and bone metastases secondary from renal cell cancer (RCC), and to identify potential risk factors for bone metastasis in newly diagnosed patients and those who have already received treatment.MethodsThe clinical data of 372 patients with RCC were reviewed from January 2000 to August 2016. The correlations between age, gender, histopathologic types, alkaline phosphotase (ALP), CEA, AFP, CA-125, CA-153, CA-199, calcium, hemoglobin (HB) and bone metastases were analyzed. And the risk factors for bone metastases in RCC were identified by multivariate logistic regression analysis. The cutoff value, sensitivity and specificity of the independent correlation factors were calculated by receiver operating characteristic (ROC) curve.ResultsThe bone is the second to the lung as a distant metastasis target site in patients with RCC. Thirty eight individuals were identified with bone metastases. Of these patients, significantly higher levels of ALP, calcium, HB were found than those without bone metastasis (P < 0.05, respectively). No significant differences were detected in CEA, AFP, CA-125, CA-153, CA-199, age, gender and histopathologic types between patients with and without bone metastases (P > 0.05, respectively). Multivariate logistic regression analysis indicated that ALP, calcium and HB were independent risk factors correlated with bone metastasis (P < 0.05, respectively). ROC curves demonstrated these factors had comparable accuracy at predicting bone metastasis (AUC were 0.749, 0.633 and 0.665, respectively). The cutoff values of ALP, calcium and HB were 105.5 U/L, 2.615 mmol/L and 111.5 g/L, respectively. The sensitivities of them were 57.9%, 36.8% and 71.1% for predicting bone metastasis, with specificities of 83.5%, 95.2% and 65.3%, respectively.ConclusionBased on our study, the concentrations of ALP, calcium and HB were potentially risk factors for bone metastasis in patients with RCC. For newly diagnosed patients, if the values of ALP>105.5 U/L, calcium>2.615 mmol/L and HB<111.5 g/L were detected, intensive monitoring and bone scanning are warranted for them.

show abstract

“…Zitvogel and colleagues have indicated the immune therapeutic benefits of extracellular vesicles in tumor. They revealed vaccination of mice with extracellular vesicles secreted from dendritic cells (DCs) had functional MHC, T-cell and costimulatory molecules [48] . The DCs were shown to stimulate an antitumor immune response and suppressed tumor growth in a T cell-dependent manner.…”

Section: Extracellular Vesicles and Immunotherapy For Osmentioning

confidence: 99%

Extracellular vesicles-mediated signaling in the osteosarcoma microenvironment: Roles and potential therapeutic targets

Lan

Zhu

Cao

et al. 2018

Journal of Bone Oncology

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most common non-hematologic malignant tumor of bone in children. It is usually characterized by a high risk of developing lung metastasis and poor prognosis. Extracellular vesicles (EVs) are cell-derived nanoparticles with a small size of 50–200 nm in diameter. As a communicator, the contents of the EVs secreted via either fusing with lysosomes for degradation and recycling or fusing with the cell plasma membrane into the extracellular environment, which play an important role in regulating the tumor microenvironment of OS and mediating the Wnt/β-catenin and TGF-β signalings. Increasing evidences suggest that EVs have significant role in OS growth, progression, metastasis and drug resistance. In this study, the roles of EVs in the physiology and pathogenesis of OS and the potential attractive therapeutic target for the treatment of OS were reviewed.

show abstract

Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach

Cited by 53 publications

References 163 publications

Andrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death receptor 4

Andrographolide sensitizes human renal carcinoma cells to TRAIL‑induced apoptosis through upregulation of death receptor 4

Risk factors for bone metastasis from renal cell cancer

Extracellular vesicles-mediated signaling in the osteosarcoma microenvironment: Roles and potential therapeutic targets

Contact Info

Product

Resources

About